Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 2.80% is 155% above its 5-year average of -5.05%, near the high end of its 5-year range (-11.75%–2.90%).
163.28% above its 12-month average of -4.42%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -0.43%.
RETURN ON ASSETS (ROA)
2.80%
RETURN ON ASSETS (ROA) AVG TTM
-4.42%
RETURN ON ASSETS (ROA) AVG 3Y
-6.73%
RETURN ON ASSETS (ROA) AVG 5Y
-5.05%
RETURN ON ASSETS (ROA) AVG 10Y
-6.80%
RETURN ON ASSETS (ROA) AVG 15Y
-7.19%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+163.28%
CURRENT VS 3Y AVG
+141.60%
CURRENT VS 5Y AVG
+155.43%
CURRENT VS 10Y AVG
+141.20%
CURRENT VS 15Y AVG
+138.94%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.47%
median of 736 covered companies
CURRENT VS SECTOR MEDIAN
+109.19%
vs the sector median at left
OptimizeRx Corp.
Market Cap
$165.58M
Return on Assets (ROA)
2.80%
TTM Avg
-4.42%
3Y Avg
-6.73%
5Y Avg
-5.05%
Market Cap
$164.16M
Return on Assets (ROA)
-38.52%
TTM Avg
-17.54%
3Y Avg
-16.16%
5Y Avg
-14.54%
Market Cap
$163.00M
Return on Assets (ROA)
-68.50%
TTM Avg
-29.78%
3Y Avg
-39.51%
5Y Avg
-30.76%
Market Cap
$162.89M
Return on Assets (ROA)
-50.88%
TTM Avg
-55.59%
3Y Avg
-49.48%
5Y Avg
-39.11%
Market Cap
$169.85M
Return on Assets (ROA)
-22.20%
TTM Avg
3.18%
3Y Avg
2.72%
5Y Avg
6.35%
Market Cap
$171.62M
Return on Assets (ROA)
-28.07%
TTM Avg
-34.40%
3Y Avg
-29.52%
5Y Avg
-36.05%
Market Cap
$159.09M
Return on Assets (ROA)
-414.72%
TTM Avg
-147.82%
3Y Avg
-101.66%
5Y Avg
-78.00%
Market Cap
$157.57M
Return on Assets (ROA)
-8.61%
TTM Avg
-9.87%
3Y Avg
-17.96%
5Y Avg
-12.40%
Market Cap
$173.23M
Return on Assets (ROA)
-32.29%
TTM Avg
-23.28%
3Y Avg
-25.06%
5Y Avg
-27.38%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| OptimizeRx Corp. (OPRX) | $165.58M | 2.80% | -4.42% | -6.73% | -5.05% |
| Quanterix Corporation (QTRX)vs › | $164.16M | -38.52% | -17.54% | -16.16% | -14.54% |
| Coherus Oncology, Inc. (CHRS)vs › | $163.00M | -68.50% | -29.78% | -39.51% | -30.76% |
| PepGen Inc. (PEPG)vs › | $162.89M | -50.88% | -55.59% | -49.48% | -39.11% |
| Organogenesis Holdings Inc. (ORGO)vs › | $169.85M | -22.20% | 3.18% | 2.72% | 6.35% |
| MediWound Ltd. (MDWD)vs › | $171.62M | -28.07% | -34.40% | -29.52% | -36.05% |
| Minerva Neurosciences, Inc. (NERV)vs › | $159.09M | -414.72% | -147.82% | -101.66% | -78.00% |
| Inogen, Inc. (INGN)vs › | $157.57M | -8.61% | -9.87% | -17.96% | -12.40% |
| ProQR Therapeutics N.V. (PRQR)vs › | $173.23M | -32.29% | -23.28% | -25.06% | -27.38% |
| Nkarta, Inc. (NKTX)vs › | $173.38M | -34.75% | -23.73% | -25.63% | -26.84% |
ROA
2.8%
ROE
3.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 2.90% |
| 2024-12-31 | -11.75% |
| 2023-12-31 | -9.58% |
| 2022-12-31 | -8.49% |
| 2021-12-31 | 0.27% |
| 2020-12-31 | -3.66% |
| 2019-12-31 | -5.55% |
| 2018-12-31 | 0.90% |
| 2017-12-31 | -21.55% |
| 2016-12-31 | -13.41% |
| 2015-12-31 | -4.83% |
| 2014-12-31 | -14.59% |
| 2013-12-31 | 5.39% |
| 2012-12-31 | -16.73% |
| 2011-12-31 | -73.32% |
| 2010-12-31 | -53.59% |
| 2009-12-31 | -511.79% |
| 2008-12-31 | -160.74% |
| 2007-12-31 | -122.55% |
